Circulating Biomarkers for Cardiotoxicity Risk Prediction

被引：0
作者：
Fei Fei Gong
Gregory J. Cascino
Gillian Murtagh
Nausheen Akhter
机构：
[1] Northwestern University Feinberg School of Medicine,Division of Cardiology
[2] Abbott Laboratories,Diagnostics Division
来源：
Current Treatment Options in Oncology | 2021年 / 22卷
关键词：
Cardiotoxicity; Biomarkers; Risk prediction; Cancer therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Improvements in cancer survival have led to the emergence of cardiovascular disease as an important determinant of adverse outcome in survivors. Cancer therapeutics–related cardiac dysfunction is the most well-known form of cardiotoxicity. However, newer cancer therapies bring a broader range of cardiotoxicities. The optimal method to identify patients at risk of these complications is unclear, but circulating biomarkers comprise one possible approach. Troponins and natriuretic peptides have garnered the broadest evidence base for cardiotoxicity risk prediction, but other markers are being investigated. In this review, we explore evidence for circulating biomarkers in cardiotoxicity prediction associated with cancer therapies.
引用
收藏
相关论文
共 385 条
[1]  
Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30
[2]  
Miller KD(2019)Cancer treatment and survivorship statistics, 2019 CA Cancer J Clin 69 363-385
[3]  
Jemal A(2019)A population-based study of cardiovascular disease mortality risk in US cancer patients Eur Heart J 40 3889-3897
[4]  
Miller KD(2002)Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 1215-1221
[5]  
Nogueira L(2020)Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations Ann Oncol 31 171-190
[6]  
Mariotto AB(2014)Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J Am Soc Echocardiogr 27 911-939
[7]  
Rowland JH(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
[8]  
Yabroff KR(1967)Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia Cancer. 20 333-353
[9]  
Alfano CM(1998)Doxorubicin-induced cardiomyopathy N Engl J Med 339 900-905
[10]  
Sturgeon KM(2012)Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 18 1639-1642
12345678910